FOXO unit Vector BioSource agrees to buy four Grifols blood collection centers in US asset deal
FOXO•Asset deal for four blood collection centers
FOXO’s Vector BioSource signed a definitive agreement to buy assets tied to four U.S. blood collection centers from Grifols Bio Supplies.
Deal structure includes an upfront cash payment, with an earnout tied to EBITDA targets in 2026-2028.
Expected revenue contribution and closing timing
Management expects the acquisition to add more than $10 million of net revenue in the 12 months after closing.
Closing is expected in Q3 or Q4 2026, subject to conditions including required FDA licensure and other regulatory authorizations.
